Apr. 16 at 12:40 PM
Citizens🏁
$WHWK and said: We are initiating coverage of Whitehawk Therapeutics, Inc. with a Market Outperform rating and price target of
$8 based on a cash per share and platform value analysis.
$ABBV $DAWN - Servier PFE LLY
Citizens added—Whitehawk is advancing three highly specific antibody- drug conjugates (ADCs) against clinically validated targets (PTK7, MUC16, SEZ6) with initial proof of concept data expected in 1H27.
With HWK-007 and HWK-016 advancing through a Phase 1 dose-escalation trial, an IND filing for HWK-206 on track for mid-2026, and a cash position of
$145.7MM, we believe shares are attractive,
with 75% downside (bear case scenario is
$1) and 150% upside (bull case scenario is
$10).
